Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Vasc Access ; 19(4): 404-408, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29529969

ABSTRACT

INTRODUCTION: We describe a hemodialysis patient who developed subclavian steal syndrome via an arteriovenous fistula after percutaneous transluminal angioplasty. CASE DESCRIPTION: A 55-year-old female with end-stage renal failure due to polycystic kidney disease had been treated with hemodialysis for 10 years. Because of an autologous arteriovenous fistula stenosis, percutaneous transluminal angioplasty was performed. After successful treatment with percutaneous transluminal angioplasty, the patient developed dizziness. Magnetic resonance imaging with angiography of the brain and neck revealed normal bilateral subclavian and carotid arteries. However, flow in the left vertebral artery was not detected in time-of-flight magnetic resonance angiography. The left vertebral artery showed completely reversed blood flow as detected by color duplex ultrasound. We also confirmed anterograde flow in the left vertebral artery by color duplex ultrasound with arteriovenous fistula compression. Arteriovenous flows before the arteriovenous fistula stenosis and post-percutaneous transluminal angioplasty were 1146 and 2239 mL/min, respectively. These findings suggested high-flow arteriovenous fistula led to the subclavian steal syndrome. The patient was subsequently treated by a flow reduction in the high-flow arteriovenous access using a modified graft inclusion technique. We decreased the arteriovenous fistula flow to 851 mL/min, which remained under 850 mL/min, 1 year later. The brain natriuretic peptide level and right-ventricular pressure also decreased after treatment. A modified graft inclusion technique was successful in decreasing the high flow of the arteriovenous fistula, and improved subclavian steal syndrome symptom and cardiac overload. CONCLUSION: This case shows that percutaneous transluminal angioplasty for an arteriovenous fistula may induce subclavian steal syndrome, and a modified graft inclusion technique was useful in improving the high flow of an arteriovenous fistula.


Subject(s)
Angioplasty/adverse effects , Arteriovenous Shunt, Surgical/adverse effects , Graft Occlusion, Vascular/therapy , Renal Dialysis , Subclavian Steal Syndrome/etiology , Upper Extremity/blood supply , Blood Flow Velocity , Female , Graft Occlusion, Vascular/diagnostic imaging , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/physiopathology , Humans , Magnetic Resonance Angiography , Middle Aged , Phlebography , Regional Blood Flow , Subclavian Steal Syndrome/diagnostic imaging , Subclavian Steal Syndrome/physiopathology , Treatment Outcome , Ultrasonography, Doppler, Color
2.
Ther Apher Dial ; 17 Suppl 1: 22-8, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23586509

ABSTRACT

To examine the efficacy of long-term administration of lanthanum carbonate, changes in serum Ca, phosphate, whole parathyroid hormone (wPTH), and ALP were examined in 40 patients who were able to tolerate dosage of lanthanum carbonate over a continuous period of 24 months. Concurrently, concomitant administration of other phosphate binders, cinacalcet, vitamin D, etc., was also examined. After 24 months, serum phosphorus levels (P levels) had decreased to within management target of guidelines, from 6.16 ± 1.44 mg/dL to 5.58 ± 1.15 mg/dL, and this effect was maintained for 2 years. There were no changes in Ca level. wPTH did not change significantly but tended to increase at 12 months. The dose of concomitantly administered calcium carbonate and sevelamer hydrochloride was reduced. The P-lowering function of lanthanum carbonate still held steady at 24 months following the start of dosage. Because of the rising trend seen in wPTH, dose of cinacalcet and/or vitamin D need to be modulated. Reducing the number of concomitantly administered phosphate binder tablets was desirable from the standpoint of patient adherence.


Subject(s)
Hyperphosphatemia/drug therapy , Kidney Failure, Chronic/therapy , Lanthanum/therapeutic use , Renal Dialysis/methods , Administration, Oral , Aged , Alkaline Phosphatase/blood , Calcium/blood , Calcium Carbonate/administration & dosage , Calcium Carbonate/therapeutic use , Cohort Studies , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Humans , Lanthanum/administration & dosage , Male , Medication Adherence , Middle Aged , Parathyroid Hormone/blood , Phosphates/blood , Polyamines/administration & dosage , Polyamines/therapeutic use , Practice Guidelines as Topic , Prospective Studies , Sevelamer , Time Factors
4.
Intern Med ; 44(10): 1084-7, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16293922

ABSTRACT

A 50-year-old woman was transferred to our hospital because of acute renal failure and thrombocytopenia. Due to rapid enlargement of the kidney, we first suspected that she had diffuse renal invasion of anaplastic carcinoma or lymphoma of the kidney. Anti-bacterial treatment for complicated urinary tract infection and hemodialysis treatment resulted in recovery of both renal function and thrombocytopenia. Serial CT study demonstrated disappearance of kidney swelling and multiple masses within the kidney. We finally made a diagnosis of acute multifocal bacterial nephritis. Timely initiation of dialysis therapy and appropriate anti-bacterial treatment was essential to rescue this case.


Subject(s)
Acute Kidney Injury/etiology , Nephritis/complications , Nephritis/microbiology , Thrombocytopenia/etiology , Acute Disease , Female , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...